Table 1.
Clinical data on patients with diabetic kidney disease and healthy control subjects (potential allograft donors)
| Clinical parameters | Patients with diabetic kidney disease (n=49) | Healthy control subjects (n=12) |
|---|---|---|
| Age, years | 56±10 | 47±9 |
| % female | 33 | 92 |
| Duration of diabetes, years | 14±9 | N/A |
| HbA1c, mmol/mol, % | 66.1; 8.2%±2.3% | |
| Baseline estimated glomerular filtration rate, mL/min/1.73 m2 | 40±22 | 89±13 |
| Baseline urine albumin to creatinine ratio, mg/mmol | 337±322 | 0.8±0.9 |
| Medication usage | ||
| RAAS nonusers | 11 | N/A |
| RAAS users | 38 | |
| DRI only | 0 | |
| ACEi only | 12 | |
| ARB only | 12 | |
| MRA only | 1 | |
| DRI + ACEi | 3 | |
| DRI + ARB | 1 | |
| DRI + MRA | 0 | |
| ACEi + ARB | 5 | |
| ACEi + MRA | 1 | |
| ARB + MRA | 1 | |
| ACEi + ARB + MRA | 2 |
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DRI, direct renin inhibitor; HbA1C, glycated hemoglobin; MRA, mineralocorticoid receptor antagonist; N/A, not applicable; RAAS, renin-angiotensin-aldosterone system.
Note: All values are presented as mean ± SD, number of patients or as otherwise indicated.